Latigo Biotherapeutics Q3 EPS $(0.55) Beats $(0.58) Estimate

Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.58) by 5.17 percent. This is a 98.14 percent increase over losses of $(29.50) per share from the same period last year.